| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2025―Okt―28 |
Risks of drug interactions of antibacterial drugs used in the treatment of nosocomial pneumonia associated with coronavirus infection |
Ya. G. Amelina, O. M. Romashov, N. V. Teplova, O. S. Gerasimova |
| 2 |
[GO] |
2024―Apr―21 |
Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19 |
S. K. Zyryanov, O. I. Butranova, A. A. Abramova |
| 3 |
[GO] |
2024―Apr―21 |
Opportunities for using telemedicine based on the COVID-19 pandemic |
F. T. Malykhin |
| 4 |
[GO] |
2024―Apr―21 |
Adverse drug events among hospitalized COVID-19 patients. Experience with the Global Trigger Tool |
S. A. Mishinova, A. S. Kolbin, E. V. Verbitskaya, N. P. Alekseeva, Yu. M. Gomon |
| 5 |
[GO] |
2023―Apr―19 |
Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19 |
S. A. Mishinova, Yu. M. Gomon, A. S. Kolbin, E. V. Verbitskaya, T. I. Galimov |
| 6 |
[GO] |
2023―Mrz―02 |
Specifics of motivation of volunteers participating in in a clinical trial of the COVID-19 vaccine |
Y. D. Belousova, V. V. Rafalsky, E. D. Kislova |
| 7 |
[GO] |
2022―Nov―15 |
The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective |
A. L. Khokhlov, J. V. Rybachkova |
| 8 |
[GO] |
2022―Mai―02 |
Lifestyle Changes in Medical Students during the COVID-19 Pandemic |
V. A. Sergeeva, T. E. Lipatova |
| 9 |
[GO] |
2022―Feb―14 |
Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg |
A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin |
| 10 |
[GO] |
2021―Aug―13 |
COVID-19: economic aspects of influenza vaccine prevention |
E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich |
| 11 |
[GO] |
2021―Mrz―12 |
Socioeconomic and global burden of COVID-19 |
A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov |
| 12 |
[GO] |
2020―Okt―28 |
Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19 |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
| 13 |
[GO] |
2020―Okt―28 |
Current and future use of angiotensin II receptor blockers in patients with COVID-19 |
A. V. Matveev, V. A. Otdelenov, D. A. Sychev |
| 14 |
[GO] |
2020―Okt―28 |
Possibilities for the use of tofacitinib in patients with COVID-19 |
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev |
| 15 |
[GO] |
2020―Okt―28 |
Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev |
| 16 |
[GO] |
2020―Okt―28 |
Possibilities for the use of anakinra in COVID-19 |
V. A. Otdelenov, A. V. Matveev, D. A. Sychev |
| 17 |
[GO] |
2020―Okt―28 |
Rationality of routine clinical use of olokizumab in COVID-19 |
V. M. Tsvetov, A. V. Matveev, D. A. Sychev |
| 18 |
[GO] |
2020―Okt―28 |
Current and future use of colchicine in patients with COVID-19 |
Yu. Yu. Kiselev, A. V. Matveev, D. A. Sychev |
| 19 |
[GO] |
2020―Okt―28 |
Current and future use of umifenovir in patients with COVID-19 |
Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, K. B. Mirzaev, V. A. Otdelenov, V. M. Tsvetov, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev |
| 20 |
[GO] |
2020―Okt―28 |
Current and future use of vitamin D3 in patients with COVID-19 |
I. N. Sychev, A. V. Matveev, D. A. Sychev |
| 21 |
[GO] |
2020―Okt―28 |
Current and future use of dipyridamole in patients with COVID-19 |
I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| 22 |
[GO] |
2020―Okt―28 |
Dexamethasone use in patients with COVID-19 |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
| 23 |
[GO] |
2020―Okt―28 |
Current and future use of remdesivir in patients with COVID-19 |
V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| 24 |
[GO] |
2020―Okt―28 |
Current and future use of favipiravir in patients with COVID-19 |
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev |
| 25 |
[GO] |
2020―Okt―28 |
Use of unlicensed drugs and off-label drug use: focus on COVID-19 |
S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko |
| 26 |
[GO] |
2020―Okt―28 |
Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge |
A. V. Krykov, V. A. Otdelenov, D. A. Sychev |
| 27 |
[GO] |
2020―Okt―28 |
Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
V. M. Tsvetov, I. N. Sychev, D. A. Sychev |
| 28 |
[GO] |
2020―Okt―28 |
Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy |
V. M. Tsvetov, Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev |
| 29 |
[GO] |
2020―Okt―28 |
Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm» |
V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev |
| 30 |
[GO] |
2020―Okt―28 |
Rationale for use mefloquine for COVID-19 treatment |
V. A. Otdelenov, K. B. Mirzaev, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev |
| 31 |
[GO] |
2020―Okt―28 |
Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention |
K. B. Mirzaev, D. A. Sychev |
| 32 |
[GO] |
2020―Okt―28 |
Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab |
K. B. Mirzaev, Yu. Yu. Kiselev, D. A. Sychev |
| 33 |
[GO] |
2020―Okt―28 |
Is it possible to use riamilovir to prevent infection and treat COVID-19? |
V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
| 34 |
[GO] |
2020―Okt―28 |
Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19? |
Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev |
| 35 |
[GO] |
2020―Okt―28 |
Could canakinumab be used for COVID-19? |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
| 36 |
[GO] |
2020―Okt―28 |
Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 |
K. A. Zagorodnikova, K. B. Mirzaev, D. A. Sychev |
| 37 |
[GO] |
2020―Okt―28 |
Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel |
V. A. Otdelenov, A. V. Krykov, D. A. Sychev |
| 38 |
[GO] |
2020―Mai―30 |
Socio-economic burden of COVID-19 in the Russian Federation |
A. S. Kolbin, D. Yu. Belousov, Yu. M. Gomon, Yu. E. Balykina, I. G. Ivanov |
